ArticlePloS one2026
EMPATH protocol: Randomized, double-blind trial of an Engaging and Mobile Prism Adaptation Treatment for spatial neglect in Home and rehabilitation settings.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05595668 (Feasibility and Effectiveness of a New Computerized Treatment Protocol for Spatial Neglect Post Stroke During Inpatient and Outpatient Rehabilitation), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Feasibility and Effectiveness of a New Computerized Treatment Protocol for Spatial Neglect Post Stroke During Inpatient and Outpatient Rehabilitation
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpatial neglect is a common attentional condition post-stroke linked to poor rehabilitation outcomes. Prism adaptation, though a promising intervention, is not yet widely used clinically due to various barriers to its implementation, including limited accessibility, the repetitive nature of the therapy, and the need for specialized equipment. This protocol aims to examine the effectiveness, feasibility, and acceptability of an engaging, mobile, computerized prism adaptation procedure (Peg-the-Mole) for treating spatial neglect in stroke inpatient and outpatient community settings. METHODS/
designThe present study uses a longitudinal, double-blind, quasi-randomized, controlled design. Forty-two individuals with right-hemisphere stroke experiencing mild to severe symptoms of neglect will be randomized into two groups: Use of Peg-the-Mole with 15-degree rightward-deviating prism goggles (intervention) or use of Peg-the-Mole with 5-degree rightward-deviating prism goggles (active control). Participants will complete 10 treatment sessions over 2 weeks, engaging with the Peg-the-Mole procedure for 15 minutes daily. Blinded assessments will take place immediately before and after treatment, as well as at one-month follow-up. The primary outcome measure will be the Star Cancellation conventional subtest of the Behavioural Inattention Test. Secondary outcomes will include additional conventional and behavioural subtests of the Behavioural Inattention Test, one subtest of the Eschenbeck Standardized Activities of Daily Living battery, the caregiver- and self-reported forms of the Halifax Neglect Impact Scale, data measuring feasibility and acceptability, prism adaptation after-effects, the Hospital Anxiety and Depression Scale, and the Fatigue Severity Scale. DISCUSSION: The Peg-the-Mole procedure has the potential to improve patient recovery and quality of life after stroke due to its gamified, portable features that promote treatment accessibility and adherence. Results from this study will help determine if the treatment can be implemented successfully in inpatient and community settings to improve neglect symptoms and daily living.
trial registrationClinicaltrials.gov, Identifier: NCT05595668; registered October 27, 2022.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.